Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact
With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact
With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact
Submitted by
admin
on April 25, 2017 - 11:03am
Source:
Endpoints
News Tags:
Novartis
Amgen
CGRP blockers
migraines
erenumab
Headline:
With late-stage data in on the CGRP migraine drug erenumab, Novartis and Amgen rework commercialization pact
Do Not Allow Advertisers to Use My Personal information
